Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.
According to this study, over the next five years the Checkpoint Inhibitors for Treating Cancer market will register a 28.0% CAGR in terms of revenue, the global market size will reach US$ 20600 million by 2024, from US$ 4690 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Checkpoint Inhibitors for Treating Cancer business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions and countries.
This study considers the Checkpoint Inhibitors for Treating Cancer value and volume generated from the sales of the following segments:
Request a sample of Checkpoint Inhibitors for Treating Cancer Market report @ http://www.arcognizance.com/enquiry-sample/245092
Segmentation by product type:
Segmentation by application:
Bladder Cancer Treatment
This report also splits the market by region:
Middle East & Africa
Access this report of Checkpoint Inhibitors for Treating Cancer Market @ http://arcognizance.com/report/global-checkpoint-inhibitors-for-treating-cancer-market-growth-2019-2024
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.
The key manufacturers covered in this report:
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
To study and analyze the global Checkpoint Inhibitors for Treating Cancer consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Checkpoint Inhibitors for Treating Cancer market by identifying its various subsegments.
Focuses on the key global Checkpoint Inhibitors for Treating Cancer manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Checkpoint Inhibitors for Treating Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Checkpoint Inhibitors for Treating Cancer submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Buy The Report @ http://www.arcognizance.com/purchase/245092
Major Point of TOC:
Chapter One: Scope of the Report
Chapter Two: Executive Summary
Chapter Three: Global Checkpoint Inhibitors for Treating Cancer by Players
Chapter Four: Checkpoint Inhibitors for Treating Cancer by Regions
Chapter Five: Americas
Chapter Six: APAC
Chapter Seven: Europe
Chapter Eight: Middle East & Africa
Chapter Nine: Market Drivers, Challenges and Trends
Chapter Ten: Marketing, Distributors and Customer
Chapter Eleven: Global Checkpoint Inhibitors for Treating Cancer Market Forecast
To Check Discount of Checkpoint Inhibitors for Treating Cancer Market @ http://www.arcognizance.com/discount/245092
www.arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics””based on the data collection facilities of big data, the face of “”business research facilities”” has changed drastically. With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “”out of the box””developments in the market.
Name: Analytical research cognizance
Address: 100 Church Street,
8th floor, Manhattan,
New York 10007
Phone: +1 (646) 434-7969 +91 90967 44448
Email: [email protected]